Search
Selected Filters
Displaying 1–10 of 11 news results
-
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
-
Foundation Fighting Blindness InSights Forum Call
The Foundation Fighting Blindness is pleased to provide an audio recording and full transcripts of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on July 24, 2019.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.
-
Foundation Fighting Blindness InSights Forum Call
The Foundation Fighting Blindness is pleased to provide an audio recording and full transcripts of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on March 22, 2019.
-
The Foundation Fighting Blindness and Dr. H. James & Carole Free Collaborate to Combat AMD
Age-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years of age in developed countries.
-
Sixth Annual Retinal Cell and Gene Therapy Innovation Summit
The Foundation Fighting Blindness (FFB), a national nonprofit focused on funding cutting-edge retinal disease research, and the Casey Eye Institute at Oregon Health & Science University will co-host the sixth annual Retinal Cell and Gene Therapy Innovation Summit in Vancouver, British Columbia, on Friday, April 26, 2019. The summit takes place just prior to the 2019 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
More than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
-
Foundation Fighting Blindness Announces Leadership Succession Plan After 45 Year Legacy
David Brint has been elected Chairman, effective July 1, 2016. Brint succeeds co-founder and current Chairman, Gordon Gund, who will remain a member of the Board of Directors and will continue to be actively involved in the Foundation’s Research Oversight Committee
-
Vision Improvements Reported in Choroideremia Gene Therapy Clinical Trial
Five of six participants in the initial study group have sustained vision improvements in their treated eyes in dim settings.
